MedPacto, Inc.

KOSDAQ 235980.KQ

MedPacto, Inc. EBITDA for the year ending December 31, 2023: USD -25.04 M

MedPacto, Inc. EBITDA is USD -25.04 M for the year ending December 31, 2023, a -33.53% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

MedPacto, Inc. EBITDA for the year ending December 31, 2022 was USD -18.76 M, a -211.83% change year over year.
MedPacto, Inc. EBITDA for the year ending December 31, 2021 was USD -6.01 M, a 74.45% change year over year.
MedPacto, Inc. EBITDA for the year ending December 31, 2020 was USD -23.54 M, a -121.40% change year over year.
MedPacto, Inc. EBITDA for the year ending December 31, 2019 was USD -10.63 M, a 67.59% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

KOSDAQ: 235980.KQ

MedPacto, Inc.

CEO	Mr. Seong-Jin Kim
IPO Date	Dec. 19, 2019
Location	South Korea
Headquarters	Borim Building
Employees	57
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea.

Key trends

Past 5 years